Meeting
2012 Breast Cancer Symposium
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
Authors
Farrah Datko
Memorial Sloan-Kettering Cancer Center
Farrah Datko , Gabriella D'Andrea , Maura Dickler , Maria Theodoulou , Shari Goldfarb , Diana Lake , Monica Fornier , Shanu Modi , Nancy Sklarin , Elizabeth Comen , Julie Fasano , Devika Gajria , Pamela Drullinsky , Conleth Murphy , Angemael Syldor , Sujata Patil , Jennifer Liu , Sarat Chandarlapaty , Clifford Hudis , Chau Dang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy,Local/Regional Therapy
Sub Track
HER2+
Clinical Trial Registration Number
NCT01276041
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 134)
DOI
10.1200/jco.2012.30.27_suppl.134
Abstract #
134
Poster Bd #
C9
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2017 ASCO Annual Meeting
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
First Author: Kazutaka Narui
Poster
2013 ASCO Annual Meeting
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
First Author: Farrah Mikhail Datko
Poster
2012 ASCO Annual Meeting
A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
First Author: Edith A. Perez